Sharp Therapeutics Corp. (TSXV:SHRX)

Sharp Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	0.44	0.51	0.55
Research & Development	2.09	1.73	1.79
Operating Expenses	2.54	2.27	2.42
Operating Income	-2.54	-2.27	-2.42
Interest Expense	-0.17	-0.17	-0.18
Other Non Operating Income (Expenses)	-0.27	-0.58	-0.65
EBT Excluding Unusual Items	-2.98	-3.02	-3.24
Other Unusual Items	-0.28	-0.54	-0.64
Pretax Income	-3.26	-3.56	-3.88
Net Income	-3.26	-3.56	-3.88
Net Income to Common	-3.26	-3.56	-3.88
Shares Outstanding (Basic)	9	4	0
Shares Outstanding (Diluted)	9	4	0
Shares Change (YoY)	107.12%	3028.62%	-
EPS (Basic)	-0.36	-0.82	-27.97
EPS (Diluted)	-0.36	-0.82	-27.97
Free Cash Flow	-3.63	-1.97	-2.05
Free Cash Flow Per Share	-0.40	-0.45	-14.77
EBITDA	-2.52	-2.24	-2.37
D&A For EBITDA	0.02	0.03	0.05
EBIT	-2.54	-2.27	-2.42

Source: S&P Global Market Intelligence. Standard template. Financial Sources.